Ting-Chao Chou

List of Publications by Year
in descending order

252 papers	28,528 citations	20817 60 h-index	5394 164 g-index
273 all docs	273 docs citations	273 times ranked	30816 citing authors

#	Article	IF	Citations
1	Efficacy of adavosertib therapy against anaplastic thyroid cancer. Endocrine-Related Cancer, 2021, 28, 311-324.	3.1	4
2	Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer. Cancers, 2021, 13, 3487.	3.7	2
3	Therapeutic inhibition of poloâ€like kinases in anaplastic thyroid cancer. Cancer Science, 2021, 112, 803-814.	3.9	4
4	Computerized quantification of drugs synergism in animal studies or in clinical trials using only ten data points. Synergy, 2019, 9, 100049.	1.1	8
5	Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer. Endocrine-Related Cancer, 2019, 26, 727-738.	3.1	8
6	Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer. Endocrine-Related Cancer, 2018, 25, 853-864.	3.1	9
7	Activity of roniciclib in medullary thyroid cancer. Oncotarget, 2018, 9, 28030-28041.	1.8	16
8	Co-exposure to low doses of the food contaminants deoxynivalenol and nivalenol has a synergistic inflammatory effect on intestinal explants. Archives of Toxicology, 2017, 91, 2677-2687.	4.2	71
9	A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer. PLoS ONE, 2017, 12, e0172315.	2.5	36
10	Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. Oncotarget, 2017, 8, 41294-41304.	1.8	33
11	Effects of roniciclib in preclinical models of anaplastic thyroid cancer. Oncotarget, 2017, 8, 67990-68000.	1.8	8
12	Abstract 4554A: Simple, efficient, and quantitative approach for determination of synergism, additive effect, and antagonism of drugsin vivousing combination index method: a proposition for clinical protocol design and regulatory synergy claims. , 2017, , .		0
13	Abstract 4554: Unified theoretical algorithms for graphics dynamic multiple transformations of dose-effect relationships with computer simulation. , 2017, , .		0
14	Drug combination in vivo using combination index method: Taxotere and T607 against colon carcinoma HCT-116 xenograft tumor in nude mice. Synergy, 2016, 3, 15-30.	1.1	45
15	Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method. American Journal of Cancer Research, 2016, 6, 97-104.	1.4	58
16	Oncolytic vaccinia virus in combination with radiation shows synergistic antitumor efficacy in pancreatic cancer. Cancer Letters, 2014, 344, 282-290.	7.2	19
17	Frequently asked questions in drug combinations and the mass-action law-based answers. Synergy, 2014, 1, 3-21.	1.1	38
18	Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer. Cancer Gene Therapy, 2014, 21, 283-289.	4.6	37

#	Article	IF	Citations
19	Oncolytic herpes simplex virus shows synergistic effects with rapamycin against triple-negative breast cancer. Journal of the American College of Surgeons, 2013, 217, S139.	0.5	0
20	Novel Antitumor Indolizino[6,7-b]indoles with Multiple Modes of Action: DNA Cross-Linking and Topoisomerase I and II Inhibition. Journal of Medicinal Chemistry, 2013, 56, 1544-1563.	6.4	57
21	Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment. PLoS ONE, 2013, 8, e77684.	2.5	35
22	Abstract 5526: Mass-action law algorithm-based computer simulation for efficient and econo-green cancer drug discovery and development.. , 2013, , .		1
23	Comparison of massâ€action law algorithmâ€based pharmacodynamics with the conventional pharmacokinetic studies. FASEB Journal, 2013, 27, 516.13.	0.5	0
24	Comparison of massâ€action law algorithmâ€based pharmacodynamics with the conventional pharmacokinetic studies. FASEB Journal, 2013, 27, 665.2.	0.5	0
25	Computerized simulation and integration of biosystems based on the massâ€action law algorithms. FASEB Journal, 2013, 27, 572.1.	0.5	0
26	Synthesis and antitumor evaluation of novel Benzo[d]pyrrolo[2,1-b]thiazole derivatives. European Journal of Medicinal Chemistry, 2012, 53, 28-40.	5.5	36
27	Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy. PLoS ONE, 2012, 7, e46726.	2.5	38
28	Abstract 1765: Potent antitumor BO-1922, derivative of indolizino[6,7-b]indole, against human colon, lung, and pancreatic cancers in xenograft model. , 2012, , .		0
29	The mass-action law based algorithms for quantitative econo-green bio-research. Integrative Biology (United Kingdom), 2011, 3, 548-559.	1.3	42
30	Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors. Journal of Neuro-Oncology, 2011, 101, 379-390.	2.9	41
31	Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates. Bioorganic and Medicinal Chemistry, 2011, 19, 1987-1998.	3.0	79
32	Novel 2â€Substituted Quinolinâ€4â€ylâ€benzenesulfonate Derivatives: Synthesis, Antiproliferative Activity, and Inhibition of Cellular Tubulin Polymerization. ChemMedChem, 2011, 6, 1119-1129.	3.2	11
33	Design, synthesis, and biological evaluation of novel water-soluble N-mustards as potential anticancer agents. Bioorganic and Medicinal Chemistry, 2011, 19, 471-485.	3.0	26
34	Novel bifunctional alkylating agents, 5,10-dihydropyrrolo[1,2-b]isoquinoline derivatives, synthesis and biological activity. Bioorganic and Medicinal Chemistry, 2011, 19, 275-286.	3.0	20
35	Rebuttal to the Response of Lee and Kong. Cancer Research, 2011, 71, 2796-2797.	0.9	1
36	Multifaceted cytoprotection by synthetic polyacetylenes inspired by the ginseng-derived natural product, panaxytriol. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14336-14341.	7.1	14

#	Article	IF	Citations
37	Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activityâ€"Letter. Cancer Research, 2011, 71, 2793-2793.	0.9	6
38	Abstract 3527: Therapeutic cure against five human xenograft tumors and strongly suppressed drug-resistant and refractory xenograft tumors in nude mice by the third generation epothilone: Iso-oxazole fludelone. , 2011, , .		0
39	Abstract 2534: Novel and stable water-soluble N-mustards with potent therapeutic efficacy against human tumor xenografts in nude mice. , 2011, , .		0
40	Abstract 3521: Alleviation of cancer chemotherapeutic agent-induced toxicity by the synthetic panaxytriol analogues of Panax Ginseng. , 2011, , .		0
41	The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. American Journal of Cancer Research, 2011, 1, 925-54.	1.4	20
42	Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. British Journal of Surgery, 2010, 97, 1385-1394.	0.3	32
43	Potent DNA-directed alkylating agents: Synthesis and biological activity of phenyl N-mustardâ€"quinoline conjugates having a urea or hydrazinecarboxamide linker. Bioorganic and Medicinal Chemistry, 2010, 18, 2285-2299.	3.0	46
44	Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Research, 2010, 70, 440-446.	0.9	4,304
45	90-kDa Heat Shock Protein Inhibition Abrogates the Topoisomerase I Poison-Induced G₂/M Checkpoint in p53-Null Tumor Cells by Depleting Chk1 and Wee1. Molecular Pharmacology, 2009, 75, 124-133.	2.3	48
46	Synthesis and in vitro cytotoxicity of 9-anilinoacridines bearing N-mustard residue on both anilino and acridine rings. European Journal of Medicinal Chemistry, 2009, 44, 3056-3059.	5.5	22
47	Novel DNA-directed alkylating agents: Design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker. Bioorganic and Medicinal Chemistry, 2009, 17, 1264-1275.	3.0	27
48	Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes. Bioorganic and Medicinal Chemistry, 2009, 17, 5614-5626.	3.0	52
49	BO-0742, a derivative of AHMA and N-mustard, has selective toxicity to drug sensitive and drug resistant leukemia cells and solid tumors. Cancer Letters, 2009, 276, 204-211.	7.2	6
50	Differential Effect of Imatinib and Synergism of Combination Treatment with Chemotherapeutic Agents in Malignant Glioma Cells. Basic and Clinical Pharmacology and Toxicology, 2009, 104, 241-252.	2.5	27
51	Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage. Bioorganic and Medicinal Chemistry, 2008, 16, 5413-5423.	3.0	56
52	Synthesis of Pluraflavin A â€œAglyconeâ€• Journal of the American Chemical Society, 2008, 130, 16786-16790.	13.7	50
53	Preclinicalversusclinical drug combination studies. Leukemia and Lymphoma, 2008, 49, 2059-2080.	1.3	233
54	Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13157-13162.	7.1	62

#	Article	IF	Citations
55	Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer. Clinical Cancer Research, 2008, 14, 1519-1528.	7.0	57
56	Synergistic apoptosis of MCF-7 breast cancer cells by 2-methoxyestradiol and bis(ethyl)norspermine. Cancer Letters, 2007, 250, 311-322.	7.2	21
57	Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacological Reviews, 2006, 58, 621-681.	16.0	4,172
58	Potent Antitumor 9-Anilinoacridines and Acridines Bearing an AlkylatingN-Mustard Residue on the Acridine Chromophore:Â Synthesis and Biological Activity. Journal of Medicinal Chemistry, 2006, 49, 3710-3718.	6.4	44
59	Radiation-Induced Cellular DNA Damage Repair Response Enhances Viral Gene Therapy Efficacy in the Treatment of Malignant Pleural Mesothelioma. Annals of Surgical Oncology, 2006, 14, 258-269.	1.5	44
60	Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. Cancer Chemotherapy and Pharmacology, 2006, 58, 640-653.	2.3	25
61	Synthesis of New Camptothecin Analogues with the E-Lactone Ring Replaced by Î±,Î²-Cyclohexenone. European Journal of Organic Chemistry, 2006, 2006, 4490-4499.	2.4	7
62	Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biology and Therapy, 2006, 5, 48-53.	3.4	57
63	5-Fluorouracil and Gemcitabine Potentiate the Efficacy of Oncolytic Herpes Viral Gene Therapy in the Treatment of Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2005, 9, 1068-1079.	1.7	52
64	Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity. Bioorganic and Medicinal Chemistry, 2005, 13, 3993-4006.	3.0	33
65	Synthesis and antitumor activity of 5-(9-acridinylamino)anisidine derivatives. Bioorganic and Medicinal Chemistry, 2005, 13, 6513-6520.	3.0	30
66	On the Remarkable Antitumor Properties of Fludelone: How We Got There. Angewandte Chemie - International Edition, 2005, 44, 2838-2850.	13.8	116
67	Cover Picture: On the Remarkable Antitumor Properties of Fludelone: How We Got There (Angew.) Tj ETQq1 1 0.784314 rgBT /Overlo	13.8	0
68	Remarkable Antitumor Properties of Fludelone: How We Got There. ChemInform, 2005, 36, no.	0.0	0
69	Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice. Cancer Chemotherapy and Pharmacology, 2005, 56, 379-390.	2.3	34
70	Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells. Journal of Cancer Research and Clinical Oncology, 2005, 131, 609-616.	2.5	5
71	TAK-220, a Novel Small-Molecule CCR5 Antagonist, Has Favorable Anti-Human Immunodeficiency Virus Interactions with Other Antiretrovirals In Vitro. Antimicrobial Agents and Chemotherapy, 2005, 49, 3483-3485.	3.2	33
72	Therapeutic Cure against Human Tumor Xenografts in Nude Mice by a Microtubule Stabilization Agent, Fludelone, via Parenteral or Oral Route. Cancer Research, 2005, 65, 9445-9454.	0.9	41

#	Article	IF	Citations
73	Radiation Therapy Potentiates Effective Oncolytic Viral Therapy in the Treatment of Lung Cancer. Annals of Thoracic Surgery, 2005, 80, 409-417.	1.3	50
74	Total Synthesis as a Resource in Drug Discovery:Â The First In Vivo Evaluation of Panaxytriol and Its Derivatives. Journal of Organic Chemistry, 2005, 70, 10375-10380.	3.2	56
75	HERPES SIMPLEX VIRUS BASED GENE THERAPY ENHANCES THE EFFICACY OF MITOMYCIN C FOR THE TREATMENT OF HUMAN BLADDER TRANSITIONAL CELL CARCINOMA. Journal of Urology, 2005, 174, 741-746.	0.4	30
76	Second generation epothilones: Discovery of fludelone and its extraordinary antitumor properties. Drugs of the Future, 2005, 30, 737.	0.1	22
77	TAK-652, a Novel CCR5 Inhibitor, has Favourable Drug Interactions with other Antiretrovirals in Vitro. Antiviral Therapy, 2005, 10, 967-968.	1.0	13
78	Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. Journal of Antimicrobial Chemotherapy, 2004, 53, 464-468.	3.0	21
79	A Comparison of Signaling Activities Induced by Taxol and Desoxyepothilone B. Journal of Chemotherapy, 2004, 16, 563-576.	1.5	10
80	Potent Crossâ€Group Neutralization of Primary Human Immunodeficiency Virus Isolates with Monoclonal Antibodiesâ€"Implications for Acquired Immunodeficiency Syndrome Vaccine. Journal of Infectious Diseases, 2004, 189, 71-74.	4.0	42
81	Upâ€regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a Î³ 1 34.5 deleted oncolytic herpes virus (G207). FASEB Journal, 2004, 18, 1001-1003.	0.5	62
82	Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4719-4722.	2.2	22
83	Discovery of (E)-9,10-Dehydroepothilones through Chemical Synthesis:Â On the Emergence of 26-Trifluoro-(E)-9,10-dehydro-12,13-desoxyepothilone B as a Promising Anticancer Drug Candidate. Journal of the American Chemical Society, 2004, 126, 10913-10922.	13.7	93
84	2-Chloro-2â€²-deoxyadenosine synergistically enhances azidothymidine cytotoxicity in azidothymidine resistant T-lymphoid cells. Biochemical and Biophysical Research Communications, 2004, 316, 518-522.	2.1	2
85	Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells. Cancer Chemotherapy and Pharmacology, 2003, 52, 41-46.	2.3	26
86	Title is missing!. Angewandte Chemie, 2003, 115, 2622-2625.	2.0	12
87	Design of Antineoplastic Agents Based on the â€œ2-Phenylnaphthalene-Typeâ€•Structural Pattern â€" Synthesis and Biological Activity Studies of 11H-Indolo[3.2-c]quinoline Derivatives.. ChemInform, 2003, 34, no.	0.0	0
88	Synthesis and Conformational Analysis of (E)-9,10-Dehydroepothilone B: A Suggestive Link between the Chemistry and Biology of Epothilones. Angewandte Chemie - International Edition, 2003, 42, 2518-2521.	13.8	46
89	Design and Total Synthesis of a Superior Family of Epothilone Analogues, which Eliminate Xenograft Tumors to a Nonrelapsable State. Angewandte Chemie - International Edition, 2003, 42, 4762-4767.	13.8	62
90	New analogues of AHMA as potential antitumor agents: synthesis and biological activity. Bioorganic and Medicinal Chemistry, 2003, 11, 4959-4969.	3.0	23

#	Article	IF	Citations
91	Design of antineoplastic agents based on the '2-phenylnaphthalene-type' structural patternâ€"synthesis and biological activity studies of 11H-indolo[3.2-c]quinoline derivatives. European Journal of Medicinal Chemistry, 2003, 38, 101-107.	5.5	64
92	Complex Target-Oriented Total Synthesis in the Drug Discovery Process:Â The Discovery of a Highly Promising Family of Second Generation Epothilones. Journal of the American Chemical Society, 2003, 125, 2899-2901.	13.7	90
93	Enhanced Hydrolytic Stability and Water Solubility of an Aromatic Nitrogen Mustard by Conjugation with Molecular Umbrellas. Bioconjugate Chemistry, 2003, 14, 667-671.	3.6	5
94	Primary African HIV Clade A and D Isolates: Effective Cross-Clade Neutralization with a Quadruple Combination of Human Monoclonal Antibodies Raised against Clade B. AIDS Research and Human Retroviruses, 2003, 19, 125-131.	1.1	25
95	Favorable Interactions between Enfuvirtide and 1-Î²-d-2,6-Diaminopurine Dioxolane In Vitro. Antimicrobial Agents and Chemotherapy, 2003, 47, 3644-3646.	3.2	7
96	Synergistic growth inhibitory effects of interferon-Î± and lovastatin on bcr-abl positive leukemic cells. International Journal of Oncology, 2003, 23, 151.	3.3	1
97	Chemotherapy: Synergism and Antagonism. , 2002, , 473-484.		4
98	p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes and Development, 2002, 16, 984-993.	5.9	181
99	Synergy Determination Issues. Journal of Virology, 2002, 76, 10577-10578.	3.4	15
100	Anti-Human Immunodeficiency Virus Interactions of SCH-C (SCH 351125), a CCR5 Antagonist, with Other Antiretroviral Agents In Vitro. Antimicrobial Agents and Chemotherapy, 2002, 46, 1336-1339.	3.2	93
101	Total Syntheses of [17]- and [18]Dehydrodesoxyepothilones B via a Concise Ring-Closing Metathesis-Based Strategy:Â Correlation of Ring Size with Biological Activity in the Epothilone Series. Journal of Organic Chemistry, 2002, 67, 7737-7740.	3.2	50
102	On the Introduction of a Trifluoromethyl Substituent in the Epothilone Setting:â€‰ Chemical Issues Related to Ring Forming Olefin Metathesis and Earliest Biological Findings. Organic Letters, 2002, 4, 4081-4084.	4.6	46
103	Probing the SAR of dEpoB via Chemical Synthesis:Â A Total Synthesis Evaluation of C26-(1,3-dioxolanyl)-12,13-desoxyepothilone B. Journal of Organic Chemistry, 2002, 67, 7730-7736.	3.2	25
104	Highly Concise Routes to Epothilones:Â The Total Synthesis and Evaluation of Epothilone 490. Journal of the American Chemical Society, 2002, 124, 9825-9832.	13.7	113
105	Antitumor AHMA Linked to DNA Minor Groove Binding Agents:Â Synthesis and Biological Evaluation. Journal of Medicinal Chemistry, 2002, 45, 4485-4493.	6.4	32
106	Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Research, 2002, 62, 6909-15.	0.9	41
107	Insights into Long-Range Structural Effects on the Stereochemistry of Aldol Condensations:Â A Practical Total Synthesis of Desoxyepothilone F. Journal of the American Chemical Society, 2001, 123, 5249-5259.	13.7	68
108	On the Interactivity of Complex Synthesis and Tumor Pharmacology in the Drug Discovery Process:Â Total Synthesis and Comparative in Vivo Evaluations of the 15-Aza Epothilones. Journal of Organic Chemistry, 2001, 66, 4369-4378.	3.2	55

#	Article	IF	Citations
109	Passive immunization against oral AIDS virus transmission: An approach to prevent mother-to-infant HIV-1 transmission?. Journal of Medical Primatology, 2001, 30, 190-196.	0.6	33
110	Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. Cancer Gene Therapy, 2001, 8, 662-668.	4.6	48
111	Postnatal Passive Immunization of Neonatal Macaques with a Triple Combination of Human Monoclonal Antibodies against Oral Simian-Human Immunodeficiency Virus Challenge. Journal of Virology, 2001, 75, 7470-7480.	3.4	158
112	The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 8113-8118.	7.1	114
113	A rigorous approach to the diagnosis of synergy among combination therapies of immunosuppressive agents. , 2001, , 183-199.		1
114	Pharmacokinetic Interactions Augment Toxicities of Sirolimus/Cyclosporine Combinations. Journal of the American Society of Nephrology: JASN, 2001, 12, 1059-1071.	6.1	200
115	In Vitro Anti-HIV-1 Synergy between Non-Nucleoside Reverse Transcriptase Inhibitors Nevirapine and Efavirenz. Antiviral Therapy, 2001, 6, 143-144.	1.0	9
116	Strong in Vitro Synergy Between the Fusion Inhibitor T-20 and the CXCR4 Blocker AMD-3100. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 99-102.	2.1	82
117	Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simianâ€“human immunodeficiency virus infection. Nature Medicine, 2000, 6, 200-206.	30.7	841
118	Strong in Vitro Synergy Between the Fusion Inhibitor T-20 and the CXCR4 Blocker AMD-3100. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 99-102.	2.1	64
119	In vitro Anti-HIV-1 Activity of sn-2-Substituted 1-O-Octadecyl-sn-Glycero-3-Phosphonoformate Analogues and Synergy with Zidovudine. Antiviral Chemistry and Chemotherapy, 2000, 11, 213-219.	0.6	9
120	Total Synthesis and Antitumor Activity of 12,13-Desoxyepothilone F:Â An Unexpected Solvolysis Problem at C15, Mediated by Remote Substitution at C21. Journal of Organic Chemistry, 2000, 65, 6525-6533.	3.2	48
121	On the Total Synthesis and Preliminary Biological Evaluations of 15(R) and 15(S) Aza-dEpoB:â€‰ A Mitsunobu Inversion at C15 in Pre-Epothilone Fragments. Organic Letters, 2000, 2, 1637-1639.	4.6	25
122	In Vitro Inhibition of HIV-1 by Met-Sdf-1Î² Alone or in Combination with Antiretroviral Drugs. Antiviral Therapy, 2000, 5, 199-204.	1.0	7
123	Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors. Annals of Oncology, 1999, 10, 601-603.	1.2	6
124	Selective, covalent modification of Â-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5686-5691.	7.1	158
125	The synthesis and evaluation of 12,13-benzodesoxyepothilone B: a highly convergent route. Tetrahedron Letters, 1999, 40, 6895-6898.	1.4	17
126	Design of Antineoplastic Agents Based on the â€œ2-Phenylnaphthalene-Typeâ€•Structural Pattern. 4. Synthesis and Biological Activity of 2-Chloro-3-(substituted phenoxy)-1,4-naphthoquinones and Related 5,8-Dihydroxy-1,4-naphthoquinones. Journal of Medicinal Chemistry, 1999, 42, 405-408.	6.4	44

#	Article	IF	Citations
127	Synthesis and Structureâ"Activity Relationships of Potential Anticancer Agents:Â Alkylcarbamates of 3-(9-Acridinylamino)-5-hydroxymethylaniline. Journal of Medicinal Chemistry, 1999, 42, 4741-4748.	6.4	28
128	Interactions Among Combinations of Two and Three Protease Inhibitors Against Drug-Susceptible and Drug-Resistant HIV-1 Isolates. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 430.	2.1	11
129	Interactions Among Combinations of Two and Three Protease Inhibitors Against Drug-Susceptible and Drug-Resistant HIV-1 Isolates. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 430.	2.1	11
130	Drug combinations: From laboratory to practice. Translational Research, 1998, 132, 6-8.	2.3	43
131	A Novel Aldol Condensation with 2-Methyl-4-pentenal and Its Application to an Improved Total Synthesis of Epothilone B. Angewandte Chemie - International Edition, 1998, 37, 2675-2678.	13.8	68
132	Synergistic Anticancer Effects of Ganciclovir/Thymidine Kinase and 5-Fluorocytosine/Cytosine Deaminase Gene Therapies. Journal of the National Cancer Institute, 1998, 90, 370-380.	6.3	139
133	Quantitation of chemopreventive synergism between (-)-epigallocatechin- 3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis, 1998, 19, 419-424.	2.8	195
134	Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 15798-15802.	7.1	163
135	Reversal of anticancer multidrug resistance by the ardeemins. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 8369-8374.	7.1	62
136	Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9642-9647.	7.1	209
137	Synergistic Neutralization of Simian-Human Immunodeficiency Virus SHIV-vpu⁺by Triple and Quadruple Combinations of Human Monoclonal Antibodies and High-Titer Anti-Human Immunodeficiency Virus Type 1 Immunoglobulins. Journal of Virology, 1998, 72, 3235-3240.	3.4	69
138	Antagonism between Human Immunodeficiency Virus Type 1 Protease Inhibitors Indinavir and Saquinavir In Vitro. Journal of Infectious Diseases, 1997, 176, 265-268.	4.0	31
139	Synergistic Neutralization of a Chimeric SIV/HIV Type 1 Virus with Combinations of Human Anti-HIV Type 1 Envelope Monoclonal Antibodies or Hyperimmune Globulins. AIDS Research and Human Retroviruses, 1997, 13, 647-656.	1.1	59
140	Remote Effects in Macrolide Formation through Ring-Forming Olefin Metathesis:Â An Application to the Synthesis of Fully Active Epothilone Congeners. Journal of the American Chemical Society, 1997, 119, 2733-2734.	13.7	180
141	Synergistic interaction between castanospermine and tacrolimus in a rat heart allograft model. Transplantation Proceedings, 1997, 29, 1259-1260.	0.6	14
142	7-Silylcamptothecins (silatecans): A new family of camptothecin antitumor agents. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 3189-3194.	2.2	62
143	Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection. Clinical and Experimental Immunology, 1997, 108, 63-68.	2.6	89
144	Stereoselective syntheses and evaluation of compounds in the 8-desmethylepothilone A series: Some surprising observations regarding their chemical and biological properties. Tetrahedron Letters, 1997, 38, 4529-4532.	1.4	52

#	Article	IF	Citations
145	Total Synthesis of(â€“)-Epothilone B: An Extension of the Suzuki Coupling Method and Insights into Structureâ€“Activity Relationships of the Epothilones. Angewandte Chemie International Edition in English, 1997, 36, 757-759.	4.4	156
146	Structureâ€“Activity Relationship of the Epothilones and the First In Vivo Comparison with Paclitaxel. Angewandte Chemie International Edition in English, 1997, 36, 2093-2096.	4.4	121
147	Totalsynthese von (â€•)â€Epothilon B: eine Erweiterung der Suzukiâ€Kupplung und Erkenntnisse Ã¼ber Strukturâ€Wirkungsâ€Beziehungen der Epothilone. Angewandte Chemie, 1997, 109, 775-777.	2.0	54
148	Staurosporine and ent-Staurosporine:â€‰ The First Total Syntheses, Prospects for a Regioselective Approach, and Activity Profiles1. Journal of the American Chemical Society, 1996, 118, 2825-2842.	13.7	135
149	Cyclopent[a]anthraquinones as DNA-Intercalating Agents with Covalent Bond Formation Potential:Â Synthesis and Biological Activity. Journal of Medicinal Chemistry, 1996, 39, 2812-2818.	6.4	11
150	The Total Synthesis of Dynemicin A Leading to Development of a Fully Contained Bioreductively Activated Enediyne Prodrug. Journal of the American Chemical Society, 1996, 118, 9509-9525.	13.7	212
151	Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 1996, 14, 709-715.	1.6	304
152	Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrobial Agents and Chemotherapy, 1996, 40, 1346-1351.	3.2	42
153	Design of antineoplastic agents on the basis of the â€œ2â€phenylâ€naphthaleneâ€typeâ€structural pattern. 3. synthesis and biological activity evaluation of 5Hâ€benzo[b]naphthoâ€[2,3â€d]pyroleâ€6,11â€dione derivatives. Journal of Heterocyclic Chemistry, 1996, 33, 113-117.	2.6	41
154	DNA Interaction and Topoisomerase II Inhibition by the Antitumor Agent 3â€²-(9-Acridinylamino)-5â€²-hydroxymethylaniline and Derivatives. Bioorganic Chemistry, 1996, 24, 229-241.	4.1	9
155	Drug Combinations and Effect Parameters of Zidovudine, Stavudine, and Nevirapine in Standardized Drug-Sensitive and Resistant HIV Type 1 Strains*. AIDS Research and Human Retroviruses, 1996, 12, 507-517.	1.1	27
156	Lamivudine or Stavudine in Two- and Three-Drug Combinations against Human Immunodeficiency Virus Type 1 Replication In Vitro. Journal of Infectious Diseases, 1996, 173, 355-364.	4.0	103
157	BENEFICIAL EFFECT OF GRAFT PERFUSION WITH ANTI-T CELL RECEPTOR MONOCLONAL ANTIBOCIES ON SURVIVAL OF SMALL BOWEL ALLOGRAFTS IN RAT RECIPIENTS TREATED WITH BREQUINAR ALONE OR IN COMBINATION WITH CYCLOSPORINE AND SIROLIMUS1. Transplantation, 1996, 61, 458-464.	1.0	20
158	EFFECTS OF THE PHARMACOKINETIC INTERACTION BETWEEN ORALLY ADMINISTERED SIROLIMUS AND CYCLOSPORINE ON THE SYNERGISTIC PROLONGATION OF HEART ALLOGRAFT SURVIVAL IN RATS1. Transplantation, 1996, 62, 986-994.	1.0	77
159	The Synergistic Effects Of Cyclosporine, Sirolimus, And Brequinar On Heart Allograft Survival In Mice. Transplantation, 1995, 59, 177-182.	1.0	38
160	Enediyne Quinone Imines: Truncated, Biologically Active Dynemicin Congeners. Angewandte Chemie International Edition in English, 1995, 33, 2477-2479.	4.4	28
161	Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: A rationale for combination therapy with chemotherapeutic agents. International Journal of Cancer, 1995, 61, 409-415.	5.1	49
162	Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemotherapy and Pharmacology, 1995, 37, 222-228.	2.3	26

#	Article	IF	Citations
163	9-Substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships. Journal of Medicinal Chemistry, 1995, 38, 3226-3235.	6.4	82
164	Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrobial Agents and Chemotherapy, 1994, 38, 656-661.	3.2	32
165	Derivatives of 1-(2-Deoxy-2-fluoro-Î²-D-arabinofuranosyl)-5-phenyluracil and 5-Benzyluracil. Synthesis and Biological Properties. Nucleosides & Nucleotides, 1994, 13, 77-94.	0.5	8
166	Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol Design. Journal of the National Cancer Institute, 1994, 86, 1517-1524.	6.3	475
167	Assessment of Synergistic and Antagonistic Effects of Chemotherapeutic Agents in vitro. Contributions To Gynecology and Obstetrics, 1994, 19, 91-107.	0.1	31
168	SYNERGISTIC IMMUNOSUPPRESSIVE ACTIONS OF CYCLOSPORINE WITH A MOUSE ANTI-RAT Î±/Î²-T CELL RECEPTOR MONOCLONAL ANTIBODY. Transplantation, 1994, 57, 1544-1547.	1.0	15
169	Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-Cell Viability Assay. Breast Cancer Research and Treatment, 1993, 28, 21-27.	2.5	21
170	Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemotherapy and Pharmacology, 1993, 31, 259-264.	2.3	56
171	A structure-activity relationship study of batracylin analogues. Pharmaceutical Research, 1993, 10, 918-923.	3.5	20
172	Synthesis of 4â€[(1,3â€diaminopyrrolo[3â€²,4â€²:4,5]pyrido[2,3â€d]â€pyrimidinâ€8â€yl)benzoyl]â€Lâ€glutamic acid as a potential antifolate. Journal of Heterocyclic Chemistry, 1993, 30, 1437-1443.	2.6	6
173	Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis. Cancer Chemotherapy and Pharmacology, 1993, 33, 245-250.	2.3	14
174	Synthesis of cyclopentanthraquinones: analogs of mitomycin C. Journal of Organic Chemistry, 1993, 58, 1680-1686.	3.2	24
175	Design of antineoplastic agents on the basis of the 2-phenylnaphthalene-type structural pattern. 2. Synthesis and biological activity studies of benzo[b]naphtho[2,3-d]furan-6,11-dione derivatives. Journal of Medicinal Chemistry, 1993, 36, 4108-4112.	6.4	54
176	Medical Management of Benign Prostatic Hyperplasia: A Canine Model Comparing the in Vivo Efficacy of Alpha-1 Adrenergic Antagonists in the Prostate. Journal of Urology, 1993, 149, 395-399.	0.4	39
177	IMMUNOSUPPRESSIVE EFFECTS OF DEFIBROTIDE. Transplantation, 1993, 56, 928-933.	1.0	17
178	THE SYNERGISTIC INTERACTIONS IN VITRO AND IN VIVO OF BREQUINAR SODIUM WITH CYCLOSPORINE OR RAPAMYCIN ALONE AND IN TRIPLE COMBINATION. Transplantation, 1993, 55, 894-900.	1.0	42
179	15 AU81, A PROSTACYCLIN ANALOG, POTENTIATES IMMUNOSUPPRESSION AND MITIGATES RENAL INJURY DUE TO CYCLOSPORINE. Transplantation, 1993, 55, 1124-1127.	1.0	18
180	Design of Antineoplastic Agents on the Basis of the "2-Phenylnaphthalene-Type" Structural Pattern. I. Synthesis of Substituted 3-Phenylquinazolones, Benzoxazolo[2,3-b]quinazolones and Benzothiazolo[2,3-b]quinazolones. Heterocycles, 1993, 35, 775.	0.7	28

#	Article	IF	Citations
181	Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. Antimicrobial Agents and Chemotherapy, 1992, 36, 808-818.	3.2	138
182	Preclinical pharmacology and pharmacokinetics of the anti-hepatitis virus agent 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil in mice and rats. Antimicrobial Agents and Chemotherapy, 1992, 36, 1472-1477.	3.2	10
183	Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. Antimicrobial Agents and Chemotherapy, 1992, 36, 1559-1562.	3.2	73
184	Human Immunodeficiency Virus Type 1 (HIV-1) Inhibitory Interactions between Protease Inhibitor Ro 31-8959 and Zidovudine, 2',3'-Dideoxycytidine, or Recombinant Interferon-ÂA against Zidovudine-Sensitive or -Resistant HIV-1 In Vitro. Journal of Infectious Diseases, 1992, 166, 1143-1146.	4.0	76
185	Three-Drug Synergistic Inhibition of HIV-1 Replication In Vitro by 3â€²-Fluoro-3â€²-Deoxythymidine, Recombinant Soluble CD4, and Recombinant Interferon-Alpha. AIDS Research and Human Retroviruses, 1992, 8, 589-595.	1.1	11
186	5â€²-Hydrogenphosphonates and 5â€²-Methylphosphonates of Sugar Modified Pyrimidine Nucleosides as Potential Anti-HIV-1 Agents.¹. Nucleosides & Nucleotides, 1992, 11, 177-196.	0.5	31
187	Overview: DNA Topoisomerase Targeted Anticancer Agents: New Trends and Developments. Current Opinion in Therapeutic Patents, 1992, 2, 1121-1139.	0.0	1
188	Synergistic Neutralization of HIV-1 by Human Monoclonal Antibodies Against the V3 Loop and the CD4-Binding Site of gp120. AIDS Research and Human Retroviruses, 1992, 8, 461-467.	1.1	122
189	Synthesis of the acridone alkaloids, glyfoline and congeners. Structure-activity relationship studies of cytotoxic acridones. Journal of Medicinal Chemistry, 1992, 35, 2703-2710.	6.4	43
190	Synthetic and Antiviral Studies of Certain Acyclic 3â€²-Azido-3â€²-Deoxythymidine (AZT) Analogues. Nucleosides & Nucleotides, 1991, 10, 1407-1416.	0.5	9
191	Fluorinated sugar analogs of potential anti-HIV-1 nucleosides. Journal of Medicinal Chemistry, 1991, 34, 1640-1646.	6.4	54
192	THE IMMUNOSUPPRESSIVE ANTAGONISM OF LOW DOSES OF FK506 AND CYCLOSPORINE. Transplantation, 1991, 52, 121-127.	1.0	32
193	SYNERGISTIC INTERACTIONS OF CYCLOSPORINE AND RAPAMYCIN TO INHIBIT IMMUNE PERFORMANCES OF NORMAL HUMAN PERIPHERAL BLOOD LYMPHOCYTES IN VITRO. Transplantation, 1991, 51, 232-238.	1.0	188
194	Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine. Antimicrobial Agents and Chemotherapy, 1991, 35, 2003-2011.	3.2	48
195	Two-Drug Combinations of Zidovudine, Didanosine, and Recombinant Interferon-Â A Inhibit Replication of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Synergistically In Vitro. Journal of Infectious Diseases, 1991, 164, 646-655.	4.0	141
196	Differential Alteration of the Anti-HIV-1 Effect of Phosphorothioate Oligonucleotide S-dC28 by AZT, Interferon-Alpha, and Dextran Sulfate. AIDS Research and Human Retroviruses, 1991, 7, 943-951.	1.1	10
197	BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrobial Agents and Chemotherapy, 1991, 35, 305-308.	3.2	176
198	ANALYSIS OF THE INTERACTIONS OF IMMUNOSUPPRESSIVE DRUGS WITH CYCLOSPORINE IN INHIBITING DNA PROLIFERATION. Transplantation, 1990, 49, 463-471.	1.0	40

#	Article	IF	Citations
199	Three-Drug Synergistic Inhibition of HIV-l Replication In Vitro by Zidovudine, Recombinant Soluble CD4, and Recombinant Interferon-alpha A. Journal of Infectious Diseases, 1990, 161, 1059-1067.	4.0	80
200	In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors. Antimicrobial Agents and Chemotherapy, 1990, 34, 82-88.	3.2	49
201	Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogs of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC). Journal of Medicinal Chemistry, 1990, 33, 2145-2150.	6.4	59
202	Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. Gynecologic Oncology, 1990, 38, 315-322.	1.4	27
203	Combined antiviral effects of paired nucleosides against guinea pig cytomegalovirus replication in vitro. Antiviral Research, 1990, 14, 249-265.	4.1	9
204	Inhibition of Simian varicella virus infection of monkeys by 1-(2-deoxy-2-fluoro-1-Î²-d-arabinofuranosyl)-5-ethyluracil (FEAU) and synergistic effects of combination with human recombinant interferon-Î². Antiviral Research, 1990, 13, 165-174.	4.1	16
205	Synergistic inhibition of human immunodeficiency virus type 1 and type 2 replication in vitro by castanospermine and 3'-azido-3'-deoxythymidine. Antimicrobial Agents and Chemotherapy, 1989, 33, 53-57.	3.2	76
206	Synergistic Inhibition of Epstein-Barr Virus: Transformation of B Lymphocytes by Â and Â Interferon and by 3'-Azido-3'-Deoxythymidine. Journal of Infectious Diseases, 1989, 159, 248-254.	4.0	25
207	Synergistic Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Replication In Vitro by Recombinant Soluble CD4 and 3'-Azido-3'-Deoxythymidine. Journal of Infectious Diseases, 1989, 159, 837-844.	4.0	62
208	Combined effects of interferon and steroid hormones on 2â€²5â€²-oligoadenylate synthetase activity in chronic lymphocytic leukemia cells. Leukemia Research, 1989, 13, 437-443.	0.8	5
209	Inhibition of cell growth and macromolecule biosynthesis of human promyelocytic leukemic cells by acridone alkaloids. Phytotherapy Research, 1989, 3, 237-242.	5.8	33
210	The enhancement of the activity of 10-propargyl-5,8-dideazafolate and 5,10-dideazatetrahydrofolate by inhibitors of dihydrofolate reductase. Advances in Enzyme Regulation, 1989, 28, 13-21.	2.6	2
211	Intercalating agents with covalent bond forming capability. A novel type of potential anticancer agents. 2. Derivatives of chrysophanol and emodin. Journal of Medicinal Chemistry, 1989, 32, 1594-1599.	6.4	78
212	Carboxypeptidase G2 enhances trimetrexate cytotoxicity in CCRF-cem cell lines sensitive and resistant to methotrexate. Advances in Enzyme Regulation, 1989, 28, 323-333.	2.6	5
213	An in Vivo Evaluation of Alpha Adrenergic Receptors in Canine Prostate. Journal of Urology, 1989, 141, 1230-1233.	0.4	12
214	Nucleosides. CXXXV. Synthesis of some 9-(2-deoxy-2-fluoro-.BETA.-D-arabinofuranosyl)-9H-purines and their biological activities.. Chemical and Pharmaceutical Bulletin, 1989, 37, 336-339.	1.3	34
215	Antagonistic interactions of hexamethylene bisacetamide in combination with 1-Î²-d-arabinofuranosylcytosine, adriamycin and harringtonine on the growth and differentiation of HL-60 cells in vitro. Leukemia Research, 1988, 12, 853-859.	0.8	3
216	Chemical synthesis and biological activities of 5-deazaaminopterin analogs bearing substituent(s) at the 5- and/or 7-position(s). Journal of Medicinal Chemistry, 1988, 31, 1209-1215.	6.4	19

#	Article	IF	Citations
217	Incorporation and metabolism of 2â€²-fluoro-5-substituted arabinosyl pyrimidines and their selective inhibition of viral DNA synthesis in herpes simplex virus type 1 (HSV-1)-infected and mock-infected Vero cells. Antiviral Research, 1988, 10, 153-166.	4.1	18
218	Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyluracil. Journal of Medicinal Chemistry, 1988, 31, 1642-1647.	6.4	16
219	Effects of Anthraquinones ofPolygonum cuspidatumon HL-60 Cells. Planta Medica, 1988, 54, 413-414.	1.3	20
220	Synergistic Interaction of 2',3'-Dideoxycytidine and Recombinant Interferon-Â-A on Replication of Human Immunodeficiency Virus Type 1. Journal of Infectious Diseases, 1988, 158, 378-385.	4.0	48
221	Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science, 1987, 235, 1376-1379.	12.6	287
222	Synthesis and biological effects of 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil. Antimicrobial Agents and Chemotherapy, 1987, 31, 1355-1358.	3.2	38
223	Effect of 9-(1,3-Dihydroxy-2-Propoxymethyl)Guanine and Recombinant Human Â Interferon Alone and in Combination on Simian Varicella Virus Infection in Monkeys. Journal of Infectious Diseases, 1987, 156, 607-614.	4.0	20
224	Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrobial Agents and Chemotherapy, 1987, 31, 168-172.	3.2	240
225	Cell differentiation effects of 2â€²-fluoro-1-Î²-d-arabinofuranosyl pyrimidines in HL-60 cells. Leukemia Research, 1987, 11, 1031-1039.	0.8	2
226	Kinetics and substrate specificity of human and canine cytidine deaminase. Biochemical Pharmacology, 1986, 35, 1199-1201.	4.4	17
227	Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis. Antimicrobial Agents and Chemotherapy, 1986, 30, 491-498.	3.2	47
228	Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon. Antimicrobial Agents and Chemotherapy, 1986, 30, 189-191.	3.2	66
229	Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells. Cancer Chemotherapy and Pharmacology, 1985, 14, 206-10.	2.3	36
230	The proliferative response of low-density human cell cultures to tumor promoters and its relevance to carcinogenic mechanismsin vitro. International Journal of Cancer, 1984, 34, 781-788.	5.1	5
231	Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 1984, 22, 27-55.	2.6	6,213
232	Synthesis of an N-aminopyrazinonium analog of cytidine. Journal of Medicinal Chemistry, 1983, 26, 283-286.	6.4	10
233	Analysis of combined drug effects: a new look at a very old problem. Trends in Pharmacological Sciences, 1983, 4, 450-454.	8.7	508
234	Kinetic properties and inhibition of Acinetobacter glutaminase-asparaginase. Biochemical Pharmacology, 1983, 32, 971-977.	4.4	20

#	Article	IF	Citations
235	Incorporation of metabolites of 2'-fluoro-5-iodo-1-Î²-d-arabinofuranosylcytosine into deoxyribonucleic acid of neoplastic and normal mammalian tissues. Biochemical Pharmacology, 1982, 31, 1103-1108.	4.4	38
236	Nucleosides. CXIX. Substrate specificity and mechanism of action of cytidine deaminases of monkey plasma and mouse kidney. Chemico-Biological Interactions, 1981, 37, 41-54.	4.0	10
237	Generalized Equations for the Analysis of Inhibitions of Michaelis-Menten and Higher-Order Kinetic Systems with Two or More Mutually Exclusive and Nonexclusive Inhibitors. FEBS Journal, 1981, 115, 207-216.	0.2	365
238	Comparison of dose-effect relationships of carcinogens following low-dose chronic exposure and high-dose single injection: an analysis by the median-effect principle. Carcinogenesis, 1980, 1, 203-213.	2.8	23
239	On the determination of availability of ligand binding sites in steady-state systems. Journal of Theoretical Biology, 1977, 65, 345-356.	1.7	34
240	Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. Journal of Theoretical Biology, 1976, 59, 253-276.	1.7	288
241	OCCURRENCE OF DEAMINATED MONOPHOSPHATE NUCLEOTIDE IN EXTRACELLULAR SITES AFTER GIVING ARABINOFURANOSYLCYTOSINE OR DEOXYCYTIDINE TO MICE. Annals of the New York Academy of Sciences, 1975, 255, 287-291.	3.8	1
242	Inhibition of ATP:l-methionine S-adenosyltrasferase of bakers' yeast by structural analogues of ATP. Biochimica Et Biophysica Acta - Biomembranes, 1973, 321, 467-474.	2.6	10
243	Regulatory properties of adenosine triphosphate-<scp>l</scp>-methionine S-adenosyltransferase of rat liver. Biochemical Journal, 1973, 135, 43-57.	3.7	46
244	A rapid assay procedure for ATP:l-methionine adenosyltransferase. Biochimica Et Biophysica Acta - Biomembranes, 1972, 276, 399-406.	2.6	47
245	Production of l-asparagine by tumor cells and the effect of asparagine analogs. Biochemical Pharmacology, 1972, 21, 39-48.	4.4	17
246	Combinatorial analysis of multiple substrateâ€”multiple product enzyme reactions. Journal of Theoretical Biology, 1972, 35, 285-297.	1.7	11
247	Mechanism of S-adenosyl-L-methionine synthesis by purified preparations of bakers' yeast. Biochemistry, 1972, 11, 1065-1073.	2.5	57
248	Effect of whole and fractionated cobra venom on sympathetic ganglionic transmission. European Journal of Pharmacology, 1969, 8, 326-330.	3.5	56
249	The binding of colchicine by sarcoma 180 cells. Biochemical Pharmacology, 1968, 17, 477-481.	4.4	22
250	The Synthesis of Some Aryl Nitrogen Mustard Derivatives of Estrogens. Journal of Medicinal Chemistry, 1967, 10, 255-257.	6.4	4
251	THE INHIBITION OF ESTERASES BY PALUDRINE. British Journal of Pharmacology and Chemotherapy, 1947, 2, 116-120.	1.4	5
252	Ch'ang Shan, a Chinese Antimalarial Herb. Science, 1946, 103, 59-59.	12.6	82